| Literature DB >> 33748373 |
Paul Enns1,2, Simon Garceau1,2, Greg Teo2, Simcha Pollock3, William J Long1,2.
Abstract
BACKGROUND: There is little evidence on outcomes of tourniquet use during bilateral total knee arthroplasty (BTKA). Tourniquet use in BTKA effects postoperative outcomes and efficiency inside the operating room. This study evaluates the safety and efficacy of simultaneous tourniquet inflation in BTKA.Entities:
Keywords: Bilateral total knee arthroplasty; Systemic complications; Tourniquet; Tourniquet inflation
Year: 2021 PMID: 33748373 PMCID: PMC7970319 DOI: 10.1016/j.artd.2021.02.005
Source DB: PubMed Journal: Arthroplast Today ISSN: 2352-3441
Figure 1Timeline representation for tourniquet management in each cohort.
Baseline cohort characteristics.
| Variable | Staged tourniquet (N = 106) | Simultaneous tourniquet (N = 179) | |||
|---|---|---|---|---|---|
| Mean or count (SD or %) | |||||
| Age at surgery (y) | 63.5 (7.6) | 65.3 (8.7) | .080 | ||
| Gender | 73 (68.9%) Female | 111 (62.0%) Female | .242 | ||
| 33 (31.1%) Male | 68 (38.0%) Male | ||||
| BMI (Kg/M2) | 31.4 (5.0) | 32.2 (5.6) | .242 | ||
| ASA score | I | 2 (1.9%) | I | 1 (0.6%) | <.001 |
| II | 72 (68.6%) | II | 61 (34.1%) | ||
| III | 31 (29.5%) | III | 116 (64.8%) | ||
| IV | 0 (0.0%) | IV | 1 (0.6%) | ||
| Smoking status | Never | 71 (67.0%) | Never | 97 (54.5%) | .041 |
| Ex-smoker | 33 (31.1%) | Ex-smoker | 68 (38.2%) | ||
| Smoker | 2 (1.9%) | Smoker | 13 (7.3%) | ||
| Cardiac history (positive) | 16 (15.1%) | 32 (17.9%) | .544 | ||
| Diabetes (positive) | 14 (13.2%) | 29 (16.2%) | .495 | ||
| Time since surgery (y) | 4.0 (1.7) | 4.0 (1.8) | .980 | ||
ASA, American Society of Anesthesiologists; BMI, body mass index; SD, standard deviation.
Independent Student’s T-Test or Mann-Whitney U Test.
χ2 Test.
Surgical outcomes according to cohorts.
| Outcomes | Staged tourniquet | Simultaneous tourniquet | |
|---|---|---|---|
| Mean or count (SD or %) | |||
| Tourniquet time (mins) | 153.8 (32.9) | 135.8 (24.9) | <.001 |
| Packed red blood cell transfusion | 14 (13.2%) | 16 (8.9%) | .256 |
| ΔHemoglobin (g/dL) | 3.2 (1.2) | 2.8 (1.0) | .004 |
| Surgical time (mins) | 158.4 (37.7) | 141.5 (25.6) | <.001 |
| Length of stay (d) | 4.0 (1.9) | 4.0 (2.2) | .812 |
Independent Student’s T-Test or Mann-Whitney U Test.
χ2 Test.
Noninferiority assessment of adverse events and complications.
| Adverse events/complications | Staged tourniquet | Simultaneous tourniquet | Δ = (staged - simultaneous) | |
|---|---|---|---|---|
| N (%) | Δ (95% Confidence intervals) | |||
| Any thrombotic event | 5 (4.7%) | 5 (2.6%) | .51 | 1.9% (−2.8%, 6.6%) |
| Cardiovascular non-myocardial infarction | 2 (1.9%) | 14 (7.1%) | .09 | −4.8% (−9.3%, −0.3%) |
| Respiratory noninfectious | 6 (5.7%) | 6 (3.1%) | .37 | 2.3% (−2.8%, 7.4%) |
| Soft tissue/wound | 2 (1.9%) | 7 (3.6%) | .71 | −1.5% (−5.2%, 2.2%) |
Fisher’s Exact test.
Figure 2Graph representation of the distribution of total time (minutes) of simultaneous tourniquet elevation.